María José Goikoetxea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
María José Goikoetxea has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
G. Gastaminza
Department of Allergology and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain
3 shared publications- Soledad Terrados
Department of Pediatric Allergy, Ramón y Cajal Hospital, Madrid, Spain
3 shared publications Be García
Hosp Univ Navarra, Dept Allergol, Pamplona, Spain
2 shared publications- Eva María Lasa
Pediatric Allergy Unit, Allergy Service, Hospital Universitario Donostia, Donostia-San Sebastián, Spain
2 shared publications - Francisco Javier Sola-Martínez
Allergy Department Hospital Universitario Ramón y Cajal Madrid Spain
2 shared publications - Marta Ferrer
Department of Allergy Clinica Universidad de Navarra Pamplona Spain
2 shared publications
Latest Publications
- 31 May 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (6) , e70364
Two cases of severe apple‐induced reactions and sensitization to gibberellin‐regulated proteins: A diagnostic challenge
- 31 May 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (6) , e70364
Two cases of severe apple‐induced reactions and sensitization to gibberellin‐regulated proteins: A diagnostic challenge
- Open Access
Ultra‐Processed Food Consumption and Childhood Allergic Diseases: Increased Risk of Asthma Onset in the SENDO Project
Background: While the role of genetic predisposition in asthma and other allergic conditions is well established, the contribution of nutritional patterns is heterogeneous and has been demonstrated in cross‐sectional studies but not in prospective cohorts. Methods: We analyzed data from 1546 participants enrolled in the SENDO cohort between January 2015 and June 2024. Children aged 4–5 years were prospectively recruited. UPF consumption was assessed at baseline and updated at the 3‐year follow‐up. Information on asthma and allergic diseases was collected at baseline and updated annually during the follow‐up. A final sample of 691 participants was classified into tertiles (T1, T2, T3) according to UPF consumption. Prevalent cases were excluded from the analysis to ensure that incident cases were included during the follow‐up. In the main analyses, we calculated the adjusted hazard ratios (HRs) and 95% CI with survival analyses. Results: After a mean follow‐up of 3.4 years, the adjusted risk for asthma in each tertile (T1, T2, T3) of UPF consumption was 2.6%, 9.9%, and 7.6% respectively (p for trend: 0.03). In the fully adjusted model of the survival analysis, children with greater UPF consumption (T2 + T3) showed a significantly higher risk of asthma (HR 3.76; 95% CI 1.15–11.51, p = 0.02) but not of AA, nor other allergic outcomes compared with their peers in the lowest tertile (T1) of UPF consumption. Conclusion: Higher UPF consumption may be associated with an increased risk of developing asthma in school‐age children.
Open AccessUltra‐Processed Food Consumption and Childhood Allergic Diseases: Increased Risk of Asthma Onset in the SENDO Project
Background: While the role of genetic predisposition in asthma and other allergic conditions is well established, the contribution of nutritional patterns is heterogeneous and has been demonstrated in cross‐sectional studies but not in prospective cohorts. Methods: We analyzed data from 1546 participants enrolled in the SENDO cohort between January 2015 and June 2024. Children aged 4–5 years were prospectively recruited. UPF consumption was assessed at baseline and updated at the 3‐year follow‐up. Information on asthma and allergic diseases was collected at baseline and updated annually during the follow‐up. A final sample of 691 participants was classified into tertiles (T1, T2, T3) according to UPF consumption. Prevalent cases were excluded from the analysis to ensure that incident cases were included during the follow‐up. In the main analyses, we calculated the adjusted hazard ratios (HRs) and 95% CI with survival analyses. Results: After a mean follow‐up of 3.4 years, the adjusted risk for asthma in each tertile (T1, T2, T3) of UPF consumption was 2.6%, 9.9%, and 7.6% respectively (p for trend: 0.03). In the fully adjusted model of the survival analysis, children with greater UPF consumption (T2 + T3) showed a significantly higher risk of asthma (HR 3.76; 95% CI 1.15–11.51, p = 0.02) but not of AA, nor other allergic outcomes compared with their peers in the lowest tertile (T1) of UPF consumption. Conclusion: Higher UPF consumption may be associated with an increased risk of developing asthma in school‐age children.
- Open Access
- 25 February 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1) , 10
Precision Medicine in Plant Food Allergy: a Systematic Review of Biomarkers Under a Clinical Approach
Plant food allergy (FA) is a major global health problem, being peanut one of the most studied allergenic foods worldwide. Biomarkers (Bms) are essential tools for precision medicine, guiding diagnosis, risk stratification, and treatment. However, evidence on their clinical applicability in plant FA remains limited and fragmented. Therefore, we aim to systematically review the Bms identified in plant FA related to several aspects of the pathology. This systematic review was performed in accordance with the PRISMA guidelines. A comprehensive search was conducted in three databases ( PubMed , Web of Sciences and Cochrane Library ) between July 2019 and July 2024. Articles were screened using predefined inclusion and exclusion criteria, and categorized into five thematic sections: sensitization, tolerance, threshold, severity and follow-up treatment. Risk-of-bias and certainty of evidence were assessed using validated tools and the GRADE approach. From the 733 articles found, 71 studies met inclusion criteria and were selected for data extraction. A majority of them were high-quality publications and predominantly involved pediatric cohorts from Europe and North America. Peanut was the most studied food, followed by nuts and wheat, while fruits and seeds were rarely represented. Across all sections, most of the studies were related to severity and tolerance. Specific IgE to whole extracts or molecular components were the most frequent Bms, followed by skin prick test. Emerging Bms were identified, although they remain in early validation stages. Risk-of-bias and certainty of evidence were primarily moderate, reflecting the exploratory nature of most of the included studies. This review highlights the predominance of classical Bms and the promise of novel candidates for future clinical integration. However, research remains allergen-, age- and region-restricted, underscoring the need for multicenter studies, representative patient samples, and validation of emerging Bms to achieve globally applicable precision medicine in plant FA.
- 25 February 2026
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 69 (1) , 10
Open AccessPrecision Medicine in Plant Food Allergy: a Systematic Review of Biomarkers Under a Clinical Approach
Plant food allergy (FA) is a major global health problem, being peanut one of the most studied allergenic foods worldwide. Biomarkers (Bms) are essential tools for precision medicine, guiding diagnosis, risk stratification, and treatment. However, evidence on their clinical applicability in plant FA remains limited and fragmented. Therefore, we aim to systematically review the Bms identified in plant FA related to several aspects of the pathology. This systematic review was performed in accordance with the PRISMA guidelines. A comprehensive search was conducted in three databases ( PubMed , Web of Sciences and Cochrane Library ) between July 2019 and July 2024. Articles were screened using predefined inclusion and exclusion criteria, and categorized into five thematic sections: sensitization, tolerance, threshold, severity and follow-up treatment. Risk-of-bias and certainty of evidence were assessed using validated tools and the GRADE approach. From the 733 articles found, 71 studies met inclusion criteria and were selected for data extraction. A majority of them were high-quality publications and predominantly involved pediatric cohorts from Europe and North America. Peanut was the most studied food, followed by nuts and wheat, while fruits and seeds were rarely represented. Across all sections, most of the studies were related to severity and tolerance. Specific IgE to whole extracts or molecular components were the most frequent Bms, followed by skin prick test. Emerging Bms were identified, although they remain in early validation stages. Risk-of-bias and certainty of evidence were primarily moderate, reflecting the exploratory nature of most of the included studies. This review highlights the predominance of classical Bms and the promise of novel candidates for future clinical integration. However, research remains allergen-, age- and region-restricted, underscoring the need for multicenter studies, representative patient samples, and validation of emerging Bms to achieve globally applicable precision medicine in plant FA.
- 9 December 2024
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 34 (6) , 395-403
Clinical Management of Plant Food Allergy in Patients Sensitized to Lipid Transfer Proteins Is Heterogeneous: Identifying the Gaps
Background: Patients sensitized to lipid transfer protein (LTP) are characterized by wide clinical variability. The lack of practical diagnostic and therapeutic guidelines complicates their management. Objective: The aim of the study was to describe the clinical approach of Spanish allergists to sensitization to LTP. Methods: We used a survey designed following the PICO method and subsequent validation using the Delphi approach. Results: The survey was completed by 224 allergists (75% women; 57.1% with >20 years of professional experience). Clinical practice for the main points of diagnosis of LTP allergy was homogeneous, except for patients with suspected hypersensitivity to nonsteroidal anti-inflammatory drugs (44.6% frequently included skin testing with LTP). Oral food challenges were not frequently performed (63.6% occasionally to never) and were generally (75.5%) used to confirm tolerance. It was common to recommend fruit skin avoidance (77.2%) and to maintain consumption of foods to which patients were sensitized but tolerant (99.1%). The results were heterogeneous for other dietary indications, modifications due to cofactors, and trace avoidance. Peach sublingual immunotherapy (SLIT) was considered very/quite effective by 55.9% of allergists. Most (79.5%) consider SLIT indicated in <25% of LTP-allergic patients based on severity (95.2%), frequency of reactions (99.4%), allergy to multiple food families (97.4%), and impairment of quality of life/nutrition (91.5%). Practice with respect to prescription of SLIT varied based on cofactor involvement. Conclusions: These data suggest that there is a need to increase evidence to reduce heterogeneity in the clinical management of LTP allergy.
- 9 December 2024
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 34 (6) , 395-403
Clinical Management of Plant Food Allergy in Patients Sensitized to Lipid Transfer Proteins Is Heterogeneous: Identifying the Gaps
Background: Patients sensitized to lipid transfer protein (LTP) are characterized by wide clinical variability. The lack of practical diagnostic and therapeutic guidelines complicates their management. Objective: The aim of the study was to describe the clinical approach of Spanish allergists to sensitization to LTP. Methods: We used a survey designed following the PICO method and subsequent validation using the Delphi approach. Results: The survey was completed by 224 allergists (75% women; 57.1% with >20 years of professional experience). Clinical practice for the main points of diagnosis of LTP allergy was homogeneous, except for patients with suspected hypersensitivity to nonsteroidal anti-inflammatory drugs (44.6% frequently included skin testing with LTP). Oral food challenges were not frequently performed (63.6% occasionally to never) and were generally (75.5%) used to confirm tolerance. It was common to recommend fruit skin avoidance (77.2%) and to maintain consumption of foods to which patients were sensitized but tolerant (99.1%). The results were heterogeneous for other dietary indications, modifications due to cofactors, and trace avoidance. Peach sublingual immunotherapy (SLIT) was considered very/quite effective by 55.9% of allergists. Most (79.5%) consider SLIT indicated in <25% of LTP-allergic patients based on severity (95.2%), frequency of reactions (99.4%), allergy to multiple food families (97.4%), and impairment of quality of life/nutrition (91.5%). Practice with respect to prescription of SLIT varied based on cofactor involvement. Conclusions: These data suggest that there is a need to increase evidence to reduce heterogeneity in the clinical management of LTP allergy.
- Open Access
- 13 March 2024
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 7 (1) , e54163
Mobile App/Web Platform for Monitoring Food Oral Immunotherapy in Children: Longitudinal Clinical Validation Study
Background: Milk and egg allergies significantly impact the quality of life, particularly in children. In this regard, food oral immunotherapy (OIT) has emerged as an effective treatment option; however, the occurrence of frequent adverse reactions poses a challenge, necessitating close monitoring during treatment. Objective: This study aims to evaluate the ability of a new mobile/web app called OITcontrol to monitor milk and egg OIT. Methods: Patients undergoing milk or egg OIT were recruited and divided into 2 groups: the active group used the OITcontrol app in conjunction with standard written monitoring methods, whereas the control group relied solely on written diaries. Investigators documented hospital doses, hospital reactions, and administered treatments on the website. Patients recorded their daily allergen home-dose intake, home reactions, and administered treatments using the app. The following variables were compared between both groups: number and severity of hospital and reported home reactions, patient’s adhesion to the OITcontrol app or written diary or both in terms of daily home-dose intake and home reactions recording, and treatment and dose adjustment compliance at home in case of reaction. Results: Sixteen patients were assigned to be monitored using the OITcontrol app along with additional written methods (active group), while 14 patients relied solely on a written paper diary (control group). A similar distribution was observed in terms of sex, age, basal characteristics, allergen treated in OIT, premedication, and sensitization profile. Active patients reported a comparable number of hospital and home reactions compared with the control group. In terms of recording system usage, 13/16 (81%) active patients used the OITcontrol app, while 10/14 (71%) control patients relied on the written diary. Among active patients, 6/16 (38%) used both methods, and 1 active patient used only written methods. However, control patients recorded home reactions more frequently than active patients (P=.009). Among active patients, the app was the preferred method for recording reactions (59/86, 69%), compared with the written diary (15/86, 17%) or both methods (12/86, 14%; P<.001). Treatment compliance in home-recorded reactions was similar between both groups (P=.15). However, treatment indications after an adverse reaction were more frequently followed (P=.04) in reactions recorded solely in the app (36/59, 61%) than in the written diary (29/71, 41%) or both systems (4/12, 33%). Moreover, compliance with dose adjustments after a moderate-severe reaction in home-recorded reactions was higher in the active group than in the control group (P<.001). Home reactions recorded only in the app (16/19, 84%) were more likely to follow dose adjustments (P<.001) than those recorded in the written diary (3/20, 15%) or using both methods (2/3, 67%). Conclusions: The OITcontrol app appears to be a valuable tool for monitoring OIT treatment in children with food allergies. It proves to be a suitable method for recording daily home dose intakes and reactions, and it seems to enhance adherence to treatment indications following an adverse reaction as well as compliance with dose adjustments in home reactions. However, additional studies are necessary to comprehensively grasp the benefits and limitations of using the OITcontrol app in the management of OIT.
- 13 March 2024
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 7 (1) , e54163
Open AccessMobile App/Web Platform for Monitoring Food Oral Immunotherapy in Children: Longitudinal Clinical Validation Study
Background: Milk and egg allergies significantly impact the quality of life, particularly in children. In this regard, food oral immunotherapy (OIT) has emerged as an effective treatment option; however, the occurrence of frequent adverse reactions poses a challenge, necessitating close monitoring during treatment. Objective: This study aims to evaluate the ability of a new mobile/web app called OITcontrol to monitor milk and egg OIT. Methods: Patients undergoing milk or egg OIT were recruited and divided into 2 groups: the active group used the OITcontrol app in conjunction with standard written monitoring methods, whereas the control group relied solely on written diaries. Investigators documented hospital doses, hospital reactions, and administered treatments on the website. Patients recorded their daily allergen home-dose intake, home reactions, and administered treatments using the app. The following variables were compared between both groups: number and severity of hospital and reported home reactions, patient’s adhesion to the OITcontrol app or written diary or both in terms of daily home-dose intake and home reactions recording, and treatment and dose adjustment compliance at home in case of reaction. Results: Sixteen patients were assigned to be monitored using the OITcontrol app along with additional written methods (active group), while 14 patients relied solely on a written paper diary (control group). A similar distribution was observed in terms of sex, age, basal characteristics, allergen treated in OIT, premedication, and sensitization profile. Active patients reported a comparable number of hospital and home reactions compared with the control group. In terms of recording system usage, 13/16 (81%) active patients used the OITcontrol app, while 10/14 (71%) control patients relied on the written diary. Among active patients, 6/16 (38%) used both methods, and 1 active patient used only written methods. However, control patients recorded home reactions more frequently than active patients (P=.009). Among active patients, the app was the preferred method for recording reactions (59/86, 69%), compared with the written diary (15/86, 17%) or both methods (12/86, 14%; P<.001). Treatment compliance in home-recorded reactions was similar between both groups (P=.15). However, treatment indications after an adverse reaction were more frequently followed (P=.04) in reactions recorded solely in the app (36/59, 61%) than in the written diary (29/71, 41%) or both systems (4/12, 33%). Moreover, compliance with dose adjustments after a moderate-severe reaction in home-recorded reactions was higher in the active group than in the control group (P<.001). Home reactions recorded only in the app (16/19, 84%) were more likely to follow dose adjustments (P<.001) than those recorded in the written diary (3/20, 15%) or using both methods (2/3, 67%). Conclusions: The OITcontrol app appears to be a valuable tool for monitoring OIT treatment in children with food allergies. It proves to be a suitable method for recording daily home dose intakes and reactions, and it seems to enhance adherence to treatment indications following an adverse reaction as well as compliance with dose adjustments in home reactions. However, additional studies are necessary to comprehensively grasp the benefits and limitations of using the OITcontrol app in the management of OIT.
- Open Access
- 2 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Mobile App/Web Platform for Monitoring Food Oral Immunotherapy in Children: Longitudinal Clinical Validation Study (Preprint)
BACKGROUND Milk and egg allergies significantly impact the quality of life, particularly in children. In this regard, food oral immunotherapy (OIT) has emerged as an effective treatment option; however, the occurrence of frequent adverse reactions poses a challenge, necessitating close monitoring during treatment. OBJECTIVE This study aims to evaluate the ability of a new mobile/web app called OITcontrol to monitor milk and egg OIT. METHODS Patients undergoing milk or egg OIT were recruited and divided into 2 groups: the active group used the OITcontrol app in conjunction with standard written monitoring methods, whereas the control group relied solely on written diaries. Investigators documented hospital doses, hospital reactions, and administered treatments on the website. Patients recorded their daily allergen home-dose intake, home reactions, and administered treatments using the app. The following variables were compared between both groups: number and severity of hospital and reported home reactions, patient’s adhesion to the OITcontrol app or written diary or both in terms of daily home-dose intake and home reactions recording, and treatment and dose adjustment compliance at home in case of reaction. RESULTS Sixteen patients were assigned to be monitored using the OITcontrol app along with additional written methods (active group), while 14 patients relied solely on a written paper diary (control group). A similar distribution was observed in terms of sex, age, basal characteristics, allergen treated in OIT, premedication, and sensitization profile. Active patients reported a comparable number of hospital and home reactions compared with the control group. In terms of recording system usage, 13/16 (81%) active patients used the OITcontrol app, while 10/14 (71%) control patients relied on the written diary. Among active patients, 6/16 (38%) used both methods, and 1 active patient used only written methods. However, control patients recorded home reactions more frequently than active patients (P=.009). Among active patients, the app was the preferred method for recording reactions (59/86, 69%), compared with the written diary (15/86, 17%) or both methods (12/86, 14%; P<.001). Treatment compliance in home-recorded reactions was similar between both groups (P=.15). However, treatment indications after an adverse reaction were more frequently followed (P=.04) in reactions recorded solely in the app (36/59, 61%) than in the written diary (29/71, 41%) or both systems (4/12, 33%). Moreover, compliance with dose adjustments after a moderate-severe reaction in home-recorded reactions was higher in the active group than in the control group (P<.001). Home reactions recorded only in the app (16/19, 84%) were more likely to follow dose adjustments (P<.001) than those recorded in the written diary (3/20, 15%) or using both methods (2/3, 67%). CONCLUSIONS The OITcontrol app appears to be a valuable tool for monitoring OIT treatment in children with food allergies. It proves to be a suitable method for recording daily home dose intakes and reactions, and it seems to enhance adherence to treatment indications following an adverse reaction as well as compliance with dose adjustments in home reactions. However, additional studies are necessary to comprehensively grasp the benefits and limitations of using the OITcontrol app in the management of OIT.
- 2 November 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMobile App/Web Platform for Monitoring Food Oral Immunotherapy in Children: Longitudinal Clinical Validation Study (Preprint)
BACKGROUND Milk and egg allergies significantly impact the quality of life, particularly in children. In this regard, food oral immunotherapy (OIT) has emerged as an effective treatment option; however, the occurrence of frequent adverse reactions poses a challenge, necessitating close monitoring during treatment. OBJECTIVE This study aims to evaluate the ability of a new mobile/web app called OITcontrol to monitor milk and egg OIT. METHODS Patients undergoing milk or egg OIT were recruited and divided into 2 groups: the active group used the OITcontrol app in conjunction with standard written monitoring methods, whereas the control group relied solely on written diaries. Investigators documented hospital doses, hospital reactions, and administered treatments on the website. Patients recorded their daily allergen home-dose intake, home reactions, and administered treatments using the app. The following variables were compared between both groups: number and severity of hospital and reported home reactions, patient’s adhesion to the OITcontrol app or written diary or both in terms of daily home-dose intake and home reactions recording, and treatment and dose adjustment compliance at home in case of reaction. RESULTS Sixteen patients were assigned to be monitored using the OITcontrol app along with additional written methods (active group), while 14 patients relied solely on a written paper diary (control group). A similar distribution was observed in terms of sex, age, basal characteristics, allergen treated in OIT, premedication, and sensitization profile. Active patients reported a comparable number of hospital and home reactions compared with the control group. In terms of recording system usage, 13/16 (81%) active patients used the OITcontrol app, while 10/14 (71%) control patients relied on the written diary. Among active patients, 6/16 (38%) used both methods, and 1 active patient used only written methods. However, control patients recorded home reactions more frequently than active patients (P=.009). Among active patients, the app was the preferred method for recording reactions (59/86, 69%), compared with the written diary (15/86, 17%) or both methods (12/86, 14%; P<.001). Treatment compliance in home-recorded reactions was similar between both groups (P=.15). However, treatment indications after an adverse reaction were more frequently followed (P=.04) in reactions recorded solely in the app (36/59, 61%) than in the written diary (29/71, 41%) or both systems (4/12, 33%). Moreover, compliance with dose adjustments after a moderate-severe reaction in home-recorded reactions was higher in the active group than in the control group (P<.001). Home reactions recorded only in the app (16/19, 84%) were more likely to follow dose adjustments (P<.001) than those recorded in the written diary (3/20, 15%) or using both methods (2/3, 67%). CONCLUSIONS The OITcontrol app appears to be a valuable tool for monitoring OIT treatment in children with food allergies. It proves to be a suitable method for recording daily home dose intakes and reactions, and it seems to enhance adherence to treatment indications following an adverse reaction as well as compliance with dose adjustments in home reactions. However, additional studies are necessary to comprehensively grasp the benefits and limitations of using the OITcontrol app in the management of OIT.
- Open Access
- 11 July 2023
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 10 (3) , 267-282
Optimising the Utility of In Vitro Tests for the Diagnosis of Drug Allergy: Insights from a Clinical Perspective
Purpose of review: To outline currently validated in vitro tests for the diagnosis of drug hypersensivity reactions (DHRs) and to provide useful strategies to optimise the utility of these tools. Recent findings: Regarding in vitro tests for DHR, the main concern, at present, is low sensitivity. Thus, most of the efforts are currently directed towards improving the existing techniques and developing new assays with better diagnostic performance. Summary: The management of DHRs is particularly challenging. Current strategies for diagnosis are focused on taking a thorough clinical history, evaluating sensitization using skin testing and performing supervised challenges. In vitro tests may potentially add information to the diagnostic algorithms for the management of DHRs. The presently available assays, however, pose significant limitations in terms of availability and validation. Maximizing their yield and accuracy, therefore, requires a tailored approach, focused on an appropriate clinical characterisation of the reaction. The time elapsed between drug administration and symptom presentation, as well as symptom duration, should be closely taken into consideration. In this review, existing validated in vitro techniques that may support the diagnosis of both immediate and non-immediate DHRs are summarised. Clues for optimizing their diagnostic yield are given.
- 11 July 2023
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 10 (3) , 267-282
Open AccessOptimising the Utility of In Vitro Tests for the Diagnosis of Drug Allergy: Insights from a Clinical Perspective
Purpose of review: To outline currently validated in vitro tests for the diagnosis of drug hypersensivity reactions (DHRs) and to provide useful strategies to optimise the utility of these tools. Recent findings: Regarding in vitro tests for DHR, the main concern, at present, is low sensitivity. Thus, most of the efforts are currently directed towards improving the existing techniques and developing new assays with better diagnostic performance. Summary: The management of DHRs is particularly challenging. Current strategies for diagnosis are focused on taking a thorough clinical history, evaluating sensitization using skin testing and performing supervised challenges. In vitro tests may potentially add information to the diagnostic algorithms for the management of DHRs. The presently available assays, however, pose significant limitations in terms of availability and validation. Maximizing their yield and accuracy, therefore, requires a tailored approach, focused on an appropriate clinical characterisation of the reaction. The time elapsed between drug administration and symptom presentation, as well as symptom duration, should be closely taken into consideration. In this review, existing validated in vitro techniques that may support the diagnosis of both immediate and non-immediate DHRs are summarised. Clues for optimizing their diagnostic yield are given.
- Open Access
- 22 July 2022
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 3, 896617
Differences in Linear Epitopes of Ara h 9 Recognition in Peanut Allergic and Tolerant, Peach Allergic Patients
Background: Peanut-allergic patients from the Mediterranean region are predominantly sensitized to the lipid transfer protein (LTP) Ara h 9, and the peach LTP Pru p 3 seems to be the primary sensitizer. However, LTP sensitization in peanut allergy is not a predictive marker for clinically relevant symptoms.Objective: We aimed to identify sequential epitopes of IgE and IgG4 from Pru p 3 and Ara h 9 in peach-allergic patients sensitized to peanuts. We also sought to determine the differences in IgE and IgG4 binding between patients who had developed peanut allergy and those tolerating peanuts.Methods: A total of 46 peach-allergic patients sensitized to peanuts were selected. A total of 35 patients were allergic to peanuts (peanut-allergic group) and 11 were tolerant to peanuts (peanut-tolerant group). We measured sIgE and sIgG4 in peanut, peach, and their recombinant allergen (Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9) with fluorescence enzyme immunoassay. We examined the IgE and IgG4 binding to sequential epitopes using a peptide microarray corresponding to linear sequences of the LTPs Ara h 9 and Pru p 3 with a library of overlapping peptides with a length of 20 amino acids (aa) and an offset of 3 aa.Results: The frequency and the intensity of IgE recognition of Ara h 9 and Pru p 3 peptides were higher in the peanut-tolerant group than in the peanut-allergic group. We found four Ara h 9 peptides (p4, p14, p21, and p25) and four Pru p 3 peptides (p1, p3, p21, and p24) with a significantly elevated IgE recognition in peanut-tolerant patients. Only one peptide of Ara h 9 (p4) recognized by IgG4 was significantly elevated in the peanut-tolerant group. The IgG4/IgE ratio of Ara h 9 peptide 4 was significantly higher in peanut-tolerant patients than in peanut-allergic patients, while no significant differences were observed in the IgG4/IgE ratio of this peptide in Pru p 3.Conclusion: Although we found significant differences in IgE and IgG4 recognition of Ara h 9 and Pru p 3 between peanut-tolerant and peanut-allergic patients (all of whom were allergic to peach), polyclonal IgE peptide recognition of both LTPs was observed in peach-allergic patients tolerating peanuts. However, the IgG4 blocking antibodies against Ara h 9 peptide 4 could provide an explanation for the absence of clinical reactivity in peanut-tolerant peach-allergic patients. Further studies are needed to validate the usefulness of IgG4 antibodies against Ara h 9 peptide 4 for peanut allergy diagnosis.
- 22 July 2022
- Published by Frontiers Media SA in Frontiers in Allergy
- Vol. 3, 896617
Open AccessDifferences in Linear Epitopes of Ara h 9 Recognition in Peanut Allergic and Tolerant, Peach Allergic Patients
Background: Peanut-allergic patients from the Mediterranean region are predominantly sensitized to the lipid transfer protein (LTP) Ara h 9, and the peach LTP Pru p 3 seems to be the primary sensitizer. However, LTP sensitization in peanut allergy is not a predictive marker for clinically relevant symptoms.Objective: We aimed to identify sequential epitopes of IgE and IgG4 from Pru p 3 and Ara h 9 in peach-allergic patients sensitized to peanuts. We also sought to determine the differences in IgE and IgG4 binding between patients who had developed peanut allergy and those tolerating peanuts.Methods: A total of 46 peach-allergic patients sensitized to peanuts were selected. A total of 35 patients were allergic to peanuts (peanut-allergic group) and 11 were tolerant to peanuts (peanut-tolerant group). We measured sIgE and sIgG4 in peanut, peach, and their recombinant allergen (Ara h 1, Ara h 2, Ara h 3, Ara h 8, and Ara h 9) with fluorescence enzyme immunoassay. We examined the IgE and IgG4 binding to sequential epitopes using a peptide microarray corresponding to linear sequences of the LTPs Ara h 9 and Pru p 3 with a library of overlapping peptides with a length of 20 amino acids (aa) and an offset of 3 aa.Results: The frequency and the intensity of IgE recognition of Ara h 9 and Pru p 3 peptides were higher in the peanut-tolerant group than in the peanut-allergic group. We found four Ara h 9 peptides (p4, p14, p21, and p25) and four Pru p 3 peptides (p1, p3, p21, and p24) with a significantly elevated IgE recognition in peanut-tolerant patients. Only one peptide of Ara h 9 (p4) recognized by IgG4 was significantly elevated in the peanut-tolerant group. The IgG4/IgE ratio of Ara h 9 peptide 4 was significantly higher in peanut-tolerant patients than in peanut-allergic patients, while no significant differences were observed in the IgG4/IgE ratio of this peptide in Pru p 3.Conclusion: Although we found significant differences in IgE and IgG4 recognition of Ara h 9 and Pru p 3 between peanut-tolerant and peanut-allergic patients (all of whom were allergic to peach), polyclonal IgE peptide recognition of both LTPs was observed in peach-allergic patients tolerating peanuts. However, the IgG4 blocking antibodies against Ara h 9 peptide 4 could provide an explanation for the absence of clinical reactivity in peanut-tolerant peach-allergic patients. Further studies are needed to validate the usefulness of IgG4 antibodies against Ara h 9 peptide 4 for peanut allergy diagnosis.
- 3 November 2016
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 28 (1) , 96-99
Induction of tolerance to different types of fish through desensitization with hake
- 3 November 2016
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 28 (1) , 96-99
Induction of tolerance to different types of fish through desensitization with hake
- Open Access
- 1 April 2016
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 26 (2) , 92-99
Is the ISAC 112 Microarray Useful in the Diagnosis of Pollinosis in Spain?
JIACI - Journal of Investigational Allergology and Clinical Immunology
- 1 April 2016
- Published by Esmon Publicidad, SA in Journal of Investigational Allergology and Clinical Immunology
- Vol. 26 (2) , 92-99
Open AccessIs the ISAC 112 Microarray Useful in the Diagnosis of Pollinosis in Spain?
JIACI - Journal of Investigational Allergology and Clinical Immunology